December 19, 2019

Mallinckrodt Terminates BRAVE Study Investigating the Efficacy and Safety of MNK-1411 in Duchenne

PPMD is disappointed to learn that Mallinckrodt has made the decision to terminate their BRAVE Study (MNK14112096). Based on the company’s statement below, the decision appears to have been the result of low enrollment and…

Learn More

January 8, 2019

Meeting Update: Inflammation in Duchenne

Last month, PPMD convened a day and half meeting – Inflammation in Duchenne: Current and New Treatment Strategies – to bring academic and clinical researchers together to discuss advancements that could be made by treating…

Learn More

August 2, 2018

Mallinckrodt Announces First Patient Enrolled in Phase 2 Study of MNK-1411 in Duchenne Muscular Dystrophy

  PPMD is excited to learn that Mallinckrodt enrolled the first patient in their Phase 2 study assessing the efficacy and safety of the investigational drug MNK-1411 (cosyntropin, also known as tetracosactide). We look forward…

Learn More